FindTrial
Sign In

Exclusive Enteral Nutrition

DIETARY_SUPPLEMENT9 trials

Sponsors

Erasmus Medical Center, Children's Hospital of Fudan University, McMaster University, University of Alabama at Birmingham, Tel-Aviv Sourasky Medical Center

Conditions

ChildrenCrohn DiseaseCrohn Disease (CD)Crohn's DiseaseEnteral Feeding IntoleranceEnteral NutritionExclusive Enteral NutritionGastrointestinal Microbiome

Phase 3

Preoperative Nutrition for Crohn's Disease Patients
Not yet recruitingNCT04398836
Tel-Aviv Sourasky Medical CenterCrohn Disease, Malnutrition
Start: 2020-09-30End: 2027-12-31Target: 144Updated: 2020-05-21

Phase 4

Top-down Infliximab Study in Kids With Crohn's Disease
CompletedNCT02517684
Erasmus Medical CenterCrohn's Disease
Start: 2015-04-30End: 2024-01-31Updated: 2024-03-05
Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD)
TerminatedNCT03833596
McMaster UniversityCrohn's Disease
Start: 2018-10-25End: 2019-11-01Updated: 2020-09-02
Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients
WithdrawnNCT04530877
Children's Hospital of Fudan UniversityCrohn's Disease, Exclusive Enteral Nutrition, Infliximab +1
Start: 2022-10-01End: 2024-09-30Updated: 2022-08-09
Combined Application of EEN in the Induction of Remission in PUC
Not yet recruitingNCT04999241
Children's Hospital of Fudan UniversityChildren, Exclusive Enteral Nutrition, Ulcerative Colitis
Start: 2025-03-01End: 2027-12-31Target: 40Updated: 2024-07-03

Unknown Phase

Effect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Gastrointestinal Microbiota for Chinese Children With Crohn's Disease
CompletedNCT03755583
Children's Hospital of Fudan UniversityCrohn Disease, Enteral Nutrition, Gastrointestinal Microbiome
Start: 2017-02-01End: 2019-12-31Updated: 2020-01-27
Exclusive Enteral Nutrition in Preterm Neonates
CompletedNCT04337710
University of Alabama at BirminghamEnteral Feeding Intolerance, Premature; Infant, Light-for-dates
Start: 2021-05-27End: 2025-09-15Updated: 2026-06-15
Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.
RecruitingNCT06912815
Xiang GaoCrohn Disease (CD)
Start: 2024-08-01End: 2026-09-30Target: 184Updated: 2025-04-06
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease
RecruitingNCT07504510
Sixth Affiliated Hospital, Sun Yat-sen UniversityCrohn's Disease
Start: 2020-06-01End: 2026-12-31Target: 300Updated: 2026-08-04

Related Papers

Early gut microbiome composition of very preterm infants randomised to receive human milk volumes of 60 ml/kg/day or more within the first 36 hours after birth.
2025-10-02
Early and exclusive enteral nutrition in infants born very preterm.
2024-06-1916 citations
Randomised clinical trial: First‐line infliximab biosimilar is cost‐effective compared to conventional treatment in paediatric Crohn's disease
Alimentary Pharmacology & Therapeutics2024-04-215 citations
Serum Immune Profiling in Paediatric Crohn’s Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments
Journal of Crohn s and Colitis2023-03-1916 citations
Evaluation of exclusive enteral nutrition and corticosteroid induction treatment in new-onset moderate-to-severe luminal paediatric Crohn’s disease
European Journal of Pediatrics2022-06-087 citations
First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
Gut2020-12-31116 citations
Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
BMJ Open Gastroenterology2016-12-0133 citations